대한부인종양학회

최신 논문

총 게시글 : 177

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial 2026-03-17 VIEW : 1
Risk stratification of groin node metastases in vulvar cancer biopsies based on histology and immunohistochemical staining 2026-03-17 VIEW : 1
Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity 2026-03-17 VIEW : 1
Fertility-sparing vs hysterectomy for uterine STUMP: A pragmatic clinical study 2026-03-17 VIEW : 1
Multi-ancestry genome-wide association analyses of polycystic ovary syndrome 2026-03-17 VIEW : 1
Incidence of Vaginal Intraepithelial Neoplasia After Hysterectomy for Cervical Cancer or Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-analysis 2026-03-17 VIEW : 1
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer 2025-12-19 VIEW : 5
Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer 2025-12-19 VIEW : 3
Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis 2025-12-19 VIEW : 4
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial 2025-12-19 VIEW : 1
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 2025-12-19 VIEW : 3
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial 2025-12-19 VIEW : 1
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial 2025-12-19 VIEW : 1
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation 2025-12-19 VIEW : 1
Dostarlimab and niraparib in primary advanced ovarian cancer 2025-12-19 VIEW : 3

1
2
3
4
5
6
7
8
9
10
11
12